The Meme-Stock obsession with pandemic days was considered to be the uprising of a normal retail investment society against the Wall Street Giants. Armed with their Zero-Fee mediation accounts on platforms such as Robinhood (Hood), a group of investors led by Reddit (RDDT) Group R/Wallstretbets, shocked the foundations of huge risk insurance funds themselves through coordinated new efforts.
Now, a few years later, the flair has returned, as a new wave of so -called memes, such as Kohl (KSS), Openndoor (open), Krispy Crempe (DNut), and Gopro (GPO). So what are other stocks that could compress? The recent CNBC reserve screenwriter emphasizes three primary criteria: a short interest percentage of floats should be greater than 30%; The company’s market limit should be between $ 50 and $ 2 billion; And the share price should be less than $ 20. Given those Meme-Stock guidelines, there are 3 names that need to be taken into account for pulse persecution.
Established in 2012, Airsculpt Technologies (Airs) operates under the elite body sculpture brand, ensuring minimally invasive body contouring procedures. Its patented Airsculpt® method removes unwanted fat and optionally moves it to areas such as breasts, hips or buttocks (eg the company’s market boundary is $ 388.5 million.
The AirsCulpt campaign YTD increased by 13.9%. Airs leads screener with a short interest rate of 53.1%and the average trade volume is 641,715 shares.
www.barchart.com
The results of AirsCulpt were consistently poor-over the last nine quarters was only one bottom line. The shares decreased by 10% Friday after 2025. Dennis Dean, the chief financier of the second quarter, also retired.
Looking to the future, Airs repeated its annual Fiskal 2025 income perspective from $ 160 to $ 170 million and adjusted EBITDA between $ 16 to $ 18 million,
In general, three analysts unanimously regarded the “stake” “detention”. The shares sell the contribution at the cost of $ 4.50.
www.barchart.com
1969 Founded in the Childrence Place (Plce) is a special children’s clothing retailer, offering branded and private clothing clothing that newborns can be known in advance, primarily through supermarket stores and online channels. The company has expanded to operate several patented brands, including Gymboree, Sugar & Jade and PJ PLACE in its portfolio.
Estimated 106.5 million. The USD market limit, the Plce shares have decreased by 56.6%. This is the second list of CNBC screening shares, with the lowest interest rate of 50.2%.
www.barchart.com
The children’s place has not missed consensus income assessments for more than a year, and the last two quarters were also loss -making.
Cash in 2025 In the first quarter, sales decreased by 9.6% from last year to 25.8 million. USD, as net losses increased to $ 1.52 for $ 1.18 for the promotion in previous years. The number of stores has also fallen to 495 from 518.
Although the cash leakage of cash decreased from the activity, it remained essential – 42.9 million. USD compared to $ 110.8 million. USD last year. In general, the “location of the children” ended with Q1 with a cash balance of $ 5.7 million. USD compared to its short-term debt level-351.5 million. USD.
The Children’s Location is limited to Wall Street coverage, with only one Hold rating and a target price of $ 6. This marks the expected approximately 32% upside down compared to the current level.
www.barchart.com
We finish our list of Zen Biopharma (ZBIO), which was founded in 2019. It is a clinical stage biopharmaceutical company focused on immunology -based treatment, especially for autoimmune and inflammatory conditions.
ZBIO shares valued at $ 657.2 million. The USD market threshold, 88.2%. This is short 50.1%.
www.barchart.com
Zen has a limited quarter -earning history, and IPO was until 2024. September 2025 In the quarter, the company reported $ 10 million.
Net cash used for operational activities increased to $ 37 million. USD from $ 19.1 million Compared to its short-term debt level-20.9 million. USD.
Zbio is the only company on this list, which is awarded the Wall Street analysts, primarily due to its products in the pipeline and research initiatives. The shares were unanimously regarded as a “strong purchase of six analysts” and the average target price is $ 32.33. This marks approximately 109% potential compared to the current level.
www.barchart.com
On the day of the publication, the Pathikrit Bose had no (directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article are only for information purposes. This article was originally published in barchart.com
